Eurofins CDMO Alphora Partners on Next-Gen ADC Production Platform
Event summary
- Eurofins CDMO Alphora's Canadian division receives advisory services and funding from NRC IRAP for an ADC production R&D project.
- Collaboration with Daresbury Proteins Ltd. aims to develop a high-yield expression platform for ADCs.
- Project seeks to streamline ADC manufacturing by integrating optimized affinity peptide tags into monoclonal antibody production.
- Initiative targets reduced manufacturing complexity, cost, and accelerated development timelines for targeted therapeutics.
The big picture
The collaboration addresses growing demand for targeted therapeutics by advancing ADC production technology. This initiative aligns with broader industry trends toward streamlined biologic manufacturing and precision medicine. The project's success could position Eurofins CDMO Alphora as a key player in next-generation ADC production, potentially impacting clinical and commercial supply chains.
What we're watching
- Technical Feasibility
- Whether the integrated expression platform can successfully eliminate traditional conjugation and purification steps.
- Commercial Viability
- The pace at which the platform can reduce ADC manufacturing costs and accelerate development timelines.
- Regulatory Pathways
- How the platform's clinic-ready ADC production will navigate regulatory approval processes.